Aytu BioPharma, Inc. (AYTU)

Over the past six months, AYTU's stock has trended down. Key events impacting the stock include the divestiture of the Consumer Health business in August 2024, which aimed to maximize shareholder value by focusing on the prescription segment. The Q1 Fiscal 2026 earnings report on November 13, 2025, resulted in a mild positive market reaction. The Q2 Fiscal 2026 earnings report on February 3, 2026, marked the commercial debut of EXXUA for major depressive disorder, with early prescription activity noted across 27 states. Aytu BioPharma's stock rating was upgraded on February 7, 2026.

The provided information does not contain specific details regarding demand seasonality for Aytu BioPharma's products and services. The company's portfolio includes treatments for ADHD and allergic conditions, which could potentially have seasonal variations in demand, but this is not explicitly stated.

Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics, primarily within the United States and internationally. The company focuses on advancing innovative medicines for complex central nervous system diseases, pediatric care, and supportive therapies. Aytu BioPharma operates within the Medical sector, specifically in the Pharmaceutical Products sub-industry. The company's portfolio includes prescription products for ADHD, allergic conditions, and fluoride-based multi-vitamin products for infants and children with fluoride deficiency. A significant recent development is the commercial launch of EXXUA, for major depressive disorder. Aytu BioPharma divested its Consumer Health segment in August 2024 to focus on its prescription pharmaceutical business.

Aytu BioPharma, Inc. focuses on commercializing novel therapeutics in the United States and internationally. The recent commercial debut of EXXUA has seen early prescription activity spanning 27 states. The company is headquartered in Englewood, Colorado, United States.

Information specifically detailing Aytu BioPharma's brand reputation in the past year is not explicitly available. However, the company has undertaken a significant strategic realignment to focus on profitability by concentrating on its prescription business. The commercial launch of EXXUA and the ongoing resilience of its ADHD portfolio contribute to its market presence.

As of February 3, 2026, Aytu BioPharma, Inc. has 40 institutional owners and shareholders holding a total of 3,824,403 shares, representing 33.49% of the stock. Major institutional shareholders include Nantahala Capital Management, LLC, Stonepine Capital Management, LLC, AWM Investment Company, Inc., and Vanguard Group Inc. Individual insiders who own company stock include Joshua R. Disbrow and Greg Pyszczymuka. As of January 2026, insiders' holdings remained unchanged at 1.46%, institutional investors at 35.50%, and mutual funds at 5.86%.